45 results on '"Francioso, Simona"'
Search Results
2. Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy
3. FRI-392-YI Chronic HDV coinfection (CHD) is characterized by a more elevated production of Middle and Large HBsAg than HBV monoinfection, that parallels HDV replicative and cytolytic activity
4. OS-094 Chronic HDV infection is sustained by an intense HBsAg production fromintegrated HBV-DNA in the setting of a limited or even absent HBV reservoir
5. Degradable starch microspheres transarterial chemoembolization (DSMs-TACE) in patients with unresectable hepatocellular carcinoma (HCC): long-term results from a single-center 137-patient cohort prospective study
6. Severe reduction of blood lysosomal acid lipase activity in cryptogenic cirrhosis: A nationwide multicentre cohort study
7. Higher levels of three HBsAg forms (Large, Middle and Small HBsAg) are associated with HDV replication and with the degree of disease and liver damage
8. The intrahepatic activity of Hepatitis Delta virus is sustained by an abundant production of HBs transcripts, mainly derived from integrated HBV-DNA, and is not strictly related to the extent of HBV reservoir
9. Stable temporal trend of HDV seroprevalence in central Italy across the last two decades with the circulation of HDV sub-genotypes 1 inducing different inflammatory stimuli
10. Results of a fast-track referral system for urgent outpatient hepatology visits
11. A simple rule to personalize standard dual therapy across all genotypes in naive chronic hepatitis C patients: The TT4 randomized trial
12. Role of MRI with hepatospecific contrast agent in the identification and characterization of focal liver lesions: pathological correlation in explanted livers
13. Liver Elasticity in NASH Patients Evaluated with Real-Time Elastography (RTE)
14. Acquisition of positively charged amino acids in HBsAg C-terminus correlates with HBV-induced liver cancer, hampers HBsAg stability and secretion and promotes cell survival
15. Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy
16. WED-203 - Stable temporal trend of HDV seroprevalence in central Italy across the last two decades with the circulation of HDV sub-genotypes 1 inducing different inflammatory stimuli
17. WED-133 - Higher levels of three HBsAg forms (Large, Middle and Small HBsAg) are associated with HDV replication and with the degree of disease and liver damage
18. TOP-106 - The intrahepatic activity of Hepatitis Delta virus is sustained by an abundant production of HBs transcripts, mainly derived from integrated HBV-DNA, and is not strictly related to the extent of HBV reservoir
19. Role of Cone-Beam CT in the Intraprocedural Evaluation of Chemoembolization of Hepatocellular Carcinoma
20. Non-alcoholic fatty liver syndrome: A hepatic consequence of common metabolic diseases
21. Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy
22. THU313 - Acquisition of positively charged amino acids in HBsAg C-terminus correlates with HBV-induced liver cancer, hampers HBsAg stability and secretion and promotes cell survival
23. Attitudes and approach to cardiovascular risk factors in Italy: results of an electronic questionnaire survey
24. Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?
25. Degradable starch microspheres transarterial chemoembolization (DSMs-TACE) in patients with unresectable hepatocellular carcinoma (HCC): long-term results from a single-center 137-patient cohort prospective study
26. Vascular anomalies of the celiac trunk and implications in treatment of HCC with TACE. Description of a case and review of the literature
27. SAT-433-Portal venous velocity and platelet count as a simple non-invasive tool to rule out the presence of varices needing treatment in patients with compensated cirrhosis
28. SAT-159-Genetic determinants in critical domains of NS5A are associated with genotype 1b HCV-induced hepatocellular carcinoma
29. SAT-195-The novel HBx mutation F30V correlates with HCC in vivo, hampers HBV replicative efficiency and enhances anti-apoptotic activity of HBx N-terminus in vitro
30. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies
31. Lack of reduction in serum alpha‐fetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hepatitis C virus‐related cirrhosis
32. Repeated Transarterial Chemoembolization with Degradable Starch Microspheres (DSMs-TACE) of Unresectable Hepatocellular Carcinoma: A Prospective Pilot Study
33. Lack of reduction in serum alpha-fetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hepatitis C virus-related cirrhosis
34. Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?
35. Severe reduction of blood lysosomal acid lipase activity in cryptogenic cirrhosis: A nationwide multicentre cohort study
36. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies
37. Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro
38. Peginterferon ??-2a and ribavirin versus peginterferon ??-2a monotherapy in early virological responders and peginterferon ??-2a and ribavirin versus peginterferon ??-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in na??ve patients with chronic hepatitis C
39. Recurrence of insulin resistant metabolic syndrome following liver transplantation
40. Association between common metabolic diseases and severity of liver steatosis
41. Virological failures to direct acting antivirals (DAA) regimens in a real life setting show frequent resistance associated variants and may require re-treatment with unconventional strategies
42. ITALIAN REAL LIFE EXPERIENCE OF RESISTANCE-GUIDED RETREATMENT IN HCV INFECTED PATIENTS WHO PREVIOUSLY FAILED A NS5A INHIBITOR-CONTAINING REGIMEN
43. Characteristic and prevalence of NS3, NS5A and NS5B resistance associated substitutions in DAA-naive and DAA-failed HCV-3 patients in Italy
44. Downstaging disease in patients with hepatocellular carcinoma outside up-to-seven criteria: Strategies using degradable starch microspheres transcatheter arterial chemo-embolization.
45. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.